{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:04:12Z","timestamp":1772780652673,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejinme.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.ejim.2015.09.009","type":"journal-article","created":{"date-parts":[[2015,9,27]],"date-time":"2015-09-27T15:47:32Z","timestamp":1443368852000},"page":"32-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Association of macrolides with overall mortality and cardiac death among patients with various infections: A meta-analysis"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2790-7839","authenticated-orcid":false,"given":"Xiang","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guiyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianli","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuntong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2015.09.009_bb0005","unstructured":"Sperryville VA. Antimicrobial therapy. Sanford guide to antimicrobial therapy. 43th edn. Antimicrobial Therapy Poc Press; 2013."},{"issue":"1","key":"10.1016\/j.ejim.2015.09.009_bb0010","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2174\/157488610789869184","article-title":"Antimicrobial agents-associated with QT interval prolongation","volume":"5","author":"Bril","year":"2010","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.ejim.2015.09.009_bb0015","unstructured":"FDA Drug Safety Communication. Azithromycin (Zithromax or Zmax) and the risk of potentially fatal heart rhythms; 2013. Database: figshare [Internet]. Accessed :http:\/\/www.fda.gov\/drugs\/drugsafety\/ucm341822.html."},{"issue":"21","key":"10.1016\/j.ejim.2015.09.009_bb0020","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1001\/archinte.159.21.2562","article-title":"Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia","volume":"159","author":"Gleason","year":"1999","journal-title":"Arch Intern Med"},{"issue":"10","key":"10.1016\/j.ejim.2015.09.009_bb0025","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.amjmed.2006.02.014","article-title":"Impact of guideline-concordant empiric antibiotic therapy in community-acquired pneumonia","volume":"119","author":"Frei","year":"2006","journal-title":"Am J Med"},{"issue":"21","key":"10.1016\/j.ejim.2015.09.009_bb0030","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1001\/jama.2014.4304","article-title":"Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia","volume":"311","author":"Mortensen","year":"2014","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.ejim.2015.09.009_bb0035","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1056\/NEJMoa1003833","article-title":"Azithromycin and the risk of cardiovascular death","volume":"366","author":"Ray","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2015.09.009_bb0040","doi-asserted-by":"crossref","unstructured":"Schembri S, Williamson PA, Short PM, Singanayagam A, Akram A, Taylor J, et al. Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort, studies. BMJ.2013; 346: f1235.","DOI":"10.1136\/bmj.f1235"},{"issue":"18","key":"10.1016\/j.ejim.2015.09.009_bb0045","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1056\/NEJMoa1300799","article-title":"Use of azithromycin and death from cardiovascular causes","volume":"368","author":"Svanstr\u00f6m","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2015.09.009_bb0050","doi-asserted-by":"crossref","unstructured":"Svanstr\u00f6m H, Pasternak B, Hviid A. Use of clarithromycin and roxithromycin and risk of cardiac death: cohort study. BMJ.2014; 349: g4930.","DOI":"10.1136\/bmj.g4930"},{"issue":"16","key":"10.1016\/j.ejim.2015.09.009_bb0055","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1001\/archinternmed.2009.265","article-title":"Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results","volume":"169","author":"Arnold","year":"2009","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.ejim.2015.09.009_bb0060","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.rmed.2011.11.017","article-title":"Guideline adherence and macrolides reduced mortality in outpatients with pneumonia","volume":"106","author":"Asadi","year":"2012","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.ejim.2015.09.009_bb0065","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1378\/chest.123.5.1503","article-title":"Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database","volume":"123","author":"Brown","year":"2003","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.ejim.2015.09.009_bb0070","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.amjmed.2006.02.014","article-title":"Impact of guideline-concordant empiric antibiotic therapy in community-acquired pneumonia","volume":"119","author":"Frei","year":"2006","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.ejim.2015.09.009_bb0075","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1370\/afm.1601","article-title":"Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death","volume":"12","author":"Rao","year":"2014","journal-title":"Ann. Fam. Med."},{"issue":"5","key":"10.1016\/j.ejim.2015.09.009_bb0080","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/2049936113501816","article-title":"Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: a narrative review based on the study of case reports","volume":"1","author":"Hancox","year":"2013","journal-title":"Ther Adv Infect Dis"},{"issue":"11","key":"10.1016\/j.ejim.2015.09.009_bb0085","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1177\/1060028013504905","article-title":"Azithromycin-induced proarrhythmia and cardiovascular death","volume":"47","author":"Howard","year":"2013","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1016\/j.ejim.2015.09.009_bb0090","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1183\/09031936.00128107","article-title":"Early mortality in patients with community-acquired pneumonia: causes and risk factors","volume":"32","author":"Garcia-Vidal","year":"2008","journal-title":"Eur. Respir. J."},{"issue":"5","key":"10.1016\/j.ejim.2015.09.009_bb0095","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1183\/09031936.04.00119503","article-title":"Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor","volume":"24","author":"Paganin","year":"2004","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.ejim.2015.09.009_bb0100","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1183\/09031936.00054108","article-title":"Impact of macrolides therapy on mortality for patients with severe sepsis due to pneumonia","volume":"33","author":"Restrepo","year":"2009","journal-title":"Eur Respir J"},{"issue":"Suppl. 55","key":"10.1016\/j.ejim.2015.09.009_bb0105","first-page":"2554","article-title":"Macrolide therapy is associated with lower 30-day mortality in patients with non-pneumonia and pneumonia severe sepsis","volume":"38","author":"Restrepo","year":"2011","journal-title":"Eur. Respir. J."},{"issue":"6","key":"10.1016\/j.ejim.2015.09.009_bb0110","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1097\/01.CCM.0000266755.75844.05","article-title":"Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock","volume":"35","author":"Rodriguez","year":"2007","journal-title":"Crit Care Med"},{"issue":"5","key":"10.1016\/j.ejim.2015.09.009_bb0115","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00228-011-1161-x","article-title":"Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases","volume":"68","author":"Zarogoulidis","year":"2012","journal-title":"Eur J ClinPharmacol"},{"issue":"1","key":"10.1016\/j.ejim.2015.09.009_bb0120","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/jac\/dkh519","article-title":"Anti-inflammatory effects of macrolides\u2014an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?","volume":"55","author":"Amsden","year":"2005","journal-title":"J. Antimicrob. Chemother"},{"issue":"1","key":"10.1016\/j.ejim.2015.09.009_bb0125","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1183\/09031936.00136712","article-title":"Long-term macrolide treatment for chronic respiratory disease","volume":"42","author":"Spagnolo","year":"2013","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.ejim.2015.09.009_bb0130","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11908-007-0016-1","article-title":"Macrolide immunomodulation of chronic respiratory diseases","volume":"9","author":"Healy","year":"2007","journal-title":"Curr Infect Dis Rep"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620515002940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620515002940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T21:24:51Z","timestamp":1567200291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620515002940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":26,"alternative-id":["S0953620515002940"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2015.09.009","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of macrolides with overall mortality and cardiac death among patients with various infections: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2015.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}